Avecho Biotechnology Limited (ASX:AVE)
Australia · Delayed Price · Currency is AUD | Market Cap | 46.36M +129.5% |
| Revenue (ttm) | 737.30K -46.6% |
| Net Income | -3.66M |
| EPS | -0.00 |
| Shares Out | 3.86B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,475,045 |
| Open | 0.0110 |
| Previous Close | 0.0110 |
| Day's Range | 0.0110 - 0.0120 |
| 52-Week Range | 0.0060 - 0.0270 |
| Beta | 1.27 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 24, 2026 |
About Avecho Biotechnology
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. Its human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. In addition, the company dev... [Read more]
Financial Performance
In 2025, Avecho Biotechnology's revenue was 1.24 million, an increase of 9.28% compared to the previous year's 1.13 million. Losses were -4.42 million, 41.5% more than in 2024.
Financial StatementsNews
Avecho Biotechnology Earnings release: Q3 2026
Avecho Biotechnology released its Q3 2026 earnings on October 27, 2026, summarizing the period's financial results.
Avecho Biotechnology Slides: Investor presentation
Avecho Biotechnology has posted slides in relation to its latest quarterly earnings report, which was published on October 12, 2026.
Avecho Biotechnology Quarterly report: H1 2026
Avecho Biotechnology has published its H1 2026 quarterly earnings report on August 25, 2026.
Ever Supreme Launches Phase IIa Clinical Trial for CAR001, Accelerating Global Market Expansion
TAICHUNG, June 29, 2026 /PRNewswire/ -- Ever Supreme Bio Technology Co., Ltd. (TWSE: 6712) announced on June 28 that CAR001, its proprietarily developed, allogeneic, "off-the-shelf" CAR-T cell therapy...
Positive interim analysis advances Avecho Phase III insomnia program
MELBOURNE, Australia, June 29, 2026 /PRNewswire/ -- Avecho Biotechnology Limited (ASX: AVE) ("Avecho" or "the Company") has announced it will continue with recruitment for its world-first Phase III in...
Avecho Biotechnology Transcript: Study update
A positive interim analysis in a large phase III trial for a proprietary CBD insomnia capsule showed efficacy and strong safety, with the trial continuing to full enrollment. The result de-risks the program, accelerates commercialization plans, and supports global licensing and regulatory strategies.
Avecho Biotechnology Slides: Study update
Avecho Biotechnology has posted slides in relation to its latest quarterly earnings report, which was published on June 23, 2026.
Avecho Biotechnology Press release: Study update
Avecho Biotechnology issued a press release on June 23, 2026, disclosing material business information to investors.
Avecho Biotechnology Transcript: Status update
A pivotal phase III trial for a TPM-enhanced CBD insomnia treatment is nearing interim analysis, with strong safety data and robust design validated by regulators. Commercial and regulatory pathways are clear, with Sandoz as a partner and global expansion planned if results are positive.
Avecho Biotechnology Slides: Status update
Avecho Biotechnology has posted slides in relation to its latest quarterly earnings report, which was published on May 24, 2026.
Avecho Biotechnology Earnings release: Q1 2026
Avecho Biotechnology released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Avecho Biotechnology Transcript: NWR Virtual Healthcare Conference
A proprietary CBD capsule for insomnia, enhanced with TPM technology, is in a pivotal phase III trial with interim results due in June. A major licensing deal with Sandoz secures Australian rights, with significant revenue potential and global expansion opportunities.
Avecho Biotechnology Annual report: H2 2025
Avecho Biotechnology has published its H2 2025 annual report on February 26, 2026.
Avecho Biotechnology Earnings release: Q4 2025
Avecho Biotechnology released its Q4 2025 earnings on January 29, 2026, summarizing the period's financial results.